CyclopharmASX:CYC 46 Net Margin % is -5,509.83% as of Dec. 2025. GuruFocus rates ASX:CYC with a GF Score™ of 46/100 and a GF Value™ of A$0.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 117 Medical Distribution companies, Cyclopharm ranks worse than 95.73% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Cyclopharm's Net Income for the
six
months ended in Dec. 2025 was A$-9.53 Mil. Cyclopharm's Revenue for the
six
months ended in Dec. 2025 was A$0.17 Mil. Therefore, Cyclopharm's net margin for the quarter that ended in Dec. 2025 was -5,509.83%.
The historical rank and industry rank for Cyclopharm's Net Margin % or its related term are showing as below:
ASX:CYC'
s Net Margin % Range Over the Past 10 Years
Min: -103.16 Med: -24.58 Max: 5.53
Current: -103.16
ASX:CYC's Net Margin % is ranked worse than 95.73% of 117
companies
in the Medical Distribution industry
Industry Median: 1.5
vs ASX:CYC: -103.16
Cyclopharm (ASX:CYC) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cyclopharm Net Margin % Related Terms
Cyclopharm Net Margin % Historical Data
* Premium members only.
The historical data trend for Cyclopharm's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cyclopharm's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyclopharm Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cyclopharm's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cyclopharm's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cyclopharm (ASX:CYC) has a Net Margin % of -5,509.83% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Cyclopharm and its competitors. According to the industry distribution chart, Cyclopharm ranks #112 out of 117 companies in the Medical Distribution industry, placing it in the top 95.7%.
Is Cyclopharm's Net Margin % too high?
Cyclopharm's current Net Margin % is -5,509.83%. Based on the distribution chart, Cyclopharm ranks #112 out of 117 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cyclopharm has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyclopharm's Net Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Cyclopharm ranks #112 out of 117 companies for Net Margin %. This places Cyclopharm in the lower half of its industry. The industry median Net Margin % is 1.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.50, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cyclopharm and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyclopharm's current Net Margin % is -5,509.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyclopharm stock overvalued right now?
Based on GuruFocus' analysis, Cyclopharm (ASX:CYC) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.84, compared to a current price of A$0.50 — trading 40.5% below its estimated fair value. The current Net Margin % is -5,509.83%. Cyclopharm's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cyclopharm (ASX:CYC), the current Net Margin % is -5,509.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyclopharm (ASX:CYC) Overvalued in 2026?
Based on GuruFocus' analysis, Cyclopharm stock appears to be undervalued.
The current stock price of A$0.50 is trading 40.5% below its estimated GF Value™ of A$0.84.
GuruFocus considers Cyclopharm to be Possible Value Trap.
Key valuation signals for ASX:CYC:
Net Margin %: -5,509.83%
GF Value™: A$0.84 vs. price of A$0.50 (40.5% below fair value)
No single metric tells the full story. See the ASX:CYC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyclopharm Ltd is a health technology company offering solutions related to functional lung ventilation imaging. Its proprietary product Technegas is a broad-spectrum diagnostic lung imaging technology product for the visualisation of pulmonary ventilation and lung function. The company sells its products to healthcare institutions and medical professionals. Maximum revenue is generated from its Technegas products and services, which include the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. Geographically, the company generates maximum revenue from its business in Europe, and the rest from Asia Pacific, Canada, the USA, and other regions.
46GF Score
Get the complete analysis for ASX:CYC
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CYC has been successfully added to your 
